• Title/Summary/Keyword: epidermal Growth factor

Search Result 628, Processing Time 0.033 seconds

Protein Motif Extraction via Feature Interval Selection

  • Sohn, In-Suk;Hwang, Chang-Ha;Ko, Jun-Su;Chiu, David;Hong, Dug-Hun
    • Journal of the Korean Data and Information Science Society
    • /
    • v.17 no.4
    • /
    • pp.1279-1287
    • /
    • 2006
  • The purpose of this paper is to present a new algorithm for extracting the consensus pattern, or motif from sequence belonging to the same family. Two methods are considered for feature interval partitioning based on equal probability and equal width interval partitioning. C2H2 zinc finger protein and epidermal growth factor protein sequences are used to demonstrate the effectiveness of the proposed algorithm for motif extraction. For two protein families, the equal width interval partitioning method performs better than the equal probability interval partitioning method.

  • PDF

HER2 induces expression of leptin in human breast epithelial cells

  • Cha, Yujin;Kang, Youjin;Moon, Aree
    • BMB Reports
    • /
    • v.45 no.12
    • /
    • pp.719-723
    • /
    • 2012
  • A close association between the obesity hormone leptin and breast cancer progression has been suggested. The present study investigated the molecular mechanism for enhanced leptin expression in breast cancer cells and its functional significance in breast cancer aggressiveness. We examined whether leptin expression level is affected by the oncoprotein human epidermal growth factor receptor2 (HER2), which is overexpressed in ~30% of breast tumors. Here, we report, for the first time, that HER2 induces transcriptional activation of leptin in MCF10A human breast epithelial cells. We also showed that p38 mitogen-activated protein kinase signaling was involved in leptin expression induced by HER2. We showed a crucial role of leptin in the invasiveness of HER2-MCF10A cells using an siRNA molecule targeting leptin. Taken together, the results indicate a molecular link between HER2 and leptin, providing supporting evidence that leptin represents a target for breast cancer therapy.

Anticancer Therapy for Breast Cancer Patients with Skin Metastases Refractory to Conventional Treatments

  • Varol, Umut;Yildiz, Ibrahim;Alacacioglu, Ahmet;Uslu, Ruchan
    • Asian Pacific Journal of Cancer Prevention
    • /
    • v.15 no.4
    • /
    • pp.1885-1887
    • /
    • 2014
  • Skin metastases of breast cancer are usually late events in the course of tumor progression and signify a poor prognosis. They may remain as a therapeutic challenge especially after failure of standard treatments. Topical interventions, together with or without radiotherapy, may only palliate the symptoms temporarily. However, there may be alternative treatment modalities for unresectable breast cancer skin metastases resistant to chemotherapy and radiotherapy. There are various genetic alterations in tumors and therapeutic potential of expression patterns for factors like epidermal growth factor receptor may have important clinical implications in case of disease refractory to the conventional treatments. Here, we clarified the therapeutic options and genetic alterations in skin metastatic breast cancer patients refractory to standard chemotherapeutics.

Development of New Drug, Epidermal Growth Factor for Chronic Diabetic Foot Ulcer

  • Yoo, Young-hyo
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 2000.04a
    • /
    • pp.3-5
    • /
    • 2000
  • Of 16 million diabetic patients in the USA, 2.4 millions have experienced diabetic foot ulcer and 67,000 have amputations every year. For treatment of diabetic foot ulcer, Americans spend more than $1 billion each year, including $36,000 per patient for complete treatment and $60,000 for each amputation. Neuropathy and ischemia, two common complications of diabetes mellitus, are the primary underlying risk factors for development of diabetic foot ulcers. Ischemic ulcers develop as a result of low perfusion pressure in the foot with inadequate blood supply, whereas neuropathic ulcers develop from loss of protective sensation. In addition, diabetes also increases the risk of infection by impairing the body's ability to eliminate bacteria. From these circumstances, results are chronic wounds with impaired healing ability.

  • PDF

Glut1 promotes cell proliferation, migration and invasion by regulating epidermal growth factor receptor and integrin signaling in triple-negative breast cancer cells

  • Oh, Sunhwa;Kim, Hyungjoo;Nam, KeeSoo;Shin, Incheol
    • BMB Reports
    • /
    • v.50 no.3
    • /
    • pp.132-137
    • /
    • 2017
  • Elevated glucose levels in cancer cells can be attributed to increased levels of glucose transporter (GLUT) proteins. Glut1 expression is increased in human malignant cells. To investigate alternative roles of Glut1 in breast cancer, we silenced Glut1 in triple-negative breast-cancer cell lines using a short hairpin RNA (shRNA) system. Glut1 silencing was verified by Western blotting and qRT-PCR. Knockdown of Glut1 resulted in decreased cell proliferation, glucose uptake, migration, and invasion through modulation of the EGFR/MAPK signaling pathway and integrin ${\beta}1$/Src/FAK signaling pathways. These results suggest that Glut1 not only plays a role as a glucose transporter, but also acts as a regulator of signaling cascades in the tumorigenesis of breast cancer.

Metachronous Liver Metastasis Resulting from Early Gastric Carcinoma after Subtotal Gastrectomy Following Endoscopic Resection: A Case Report

  • Oh, Sung Jin;Suh, Byoung Jo
    • Journal of Gastric Cancer
    • /
    • v.15 no.2
    • /
    • pp.139-142
    • /
    • 2015
  • Hepatic metastasis of early gastric cancer (EGC) following subtotal gastrectomy with lymphadenectomy is rare. We report the case of a 61-year-old male patient who was diagnosed with EGC that was initially treated using endoscopic submucosal dissection (ESD) and subsequently underwent laparoscopic subtotal gastrectomy. Histopathological examination of the patient's ESD specimen showed a moderately differentiated tubular adenocarcinoma invading the submucosa without lymphatic invasion. The deep margin of the specimen was positive for adenocarcinoma, and he subsequently underwent laparoscopic distal gastrectomy. The patient developed liver metastasis 15 months after the operation and then underwent liver resection. Histology of the resected specimen confirmed the diagnosis of two foci of metastatic adenocarcinoma originating from stomach cancer. Immunohistochemical analysis of the specimen demonstrated overexpression of human epidermal growth factor receptor 2. The patient was treated with trastuzumab in combination with chemotherapy consisting of capecitabine and cisplatin. Twenty-four months after the operation, the patient remained free of recurrence.

Synthesis and Characterization of the Conjugate of Poly(ethylene glycol) with Human Epidermal Growth Factor(hEGF) and its Cell Proliferation Effect

  • Kim, Koi-Ho;Jeong, See-Hwa;Takashi Hirano;Park, Soo-Nam
    • Journal of the Society of Cosmetic Scientists of Korea
    • /
    • v.25 no.1
    • /
    • pp.107-119
    • /
    • 1999
  • 3 Kinds of PEG-hEGF conjugate, PEG5-hEGF, PEG5-hEGF, PEG10-hEGF, were synthesized. Major fractions containing 2 chains of PEG were separated by preparative GPC. Molecular weight was estimated by GPC-MALLS, TOF-Mass and SDS-PAGE, and the data were well corresponding to calculated one. The cell proliferation effect of the conjugates was evaluated, Indicating that the conjugate bound to longer chain PEG exhibits lower activity. Selective modification of hEGF and activity preservation of PEG-hEGF conjugate are undergoing.

  • PDF

Specific Cell-Signal Targets for Cancer Chemotherapy

  • Aszalos, Adorjan
    • Archives of Pharmacal Research
    • /
    • v.25 no.1
    • /
    • pp.1-10
    • /
    • 2002
  • Attempts to develop drugs, specific for cancer cells, are dealt here according to the intended cell-target. While many target specific drugs were developed, they reach only moderate successes in clinics for reasons, such as, delivery problem, lack of in vivo efficacy or toxicity. However, recent efforts focusing on the diversity of tyrosine kinases, participating in cell-signal transduction, brought fruit. The first such drug, Givec, approved by the USFDA recently, is used in clinics with great success to threat CML. The drug inhibits tyrosin kinase of bcr-abl, c-abl and v-abl. Work is progressing on other tyrosin kinase inhibitors and on other type of specific cancer cell signal protein inhibitors. These efforts are hoped to yield better cures for cancer in the near future.